Danaher Co. (NYSE:DHR) declared a quarterly dividend on Tuesday, February 23rd, RTT News reports. Shareholders of record on Friday, March 26th will be paid a dividend of 0.21 per share by the conglomerate on Friday, April 30th. This represents a $0.84 dividend on an annualized basis and a yield of 0.38%. This is a positive change from Danaher's previous quarterly dividend of $0.18.
Danaher has increased its dividend payment by 28.6% over the last three years and has increased its dividend every year for the last 4 years.
Danaher stock traded down $1.87 during trading hours on Tuesday, reaching $223.63. The company had a trading volume of 130,423 shares, compared to its average volume of 2,625,056. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.08 and a quick ratio of 1.68. The company has a 50-day moving average price of $237.66 and a 200 day moving average price of $223.22. The firm has a market cap of $158.86 billion, a price-to-earnings ratio of 45.18, a P/E/G ratio of 1.92 and a beta of 0.72. Danaher has a 12-month low of $119.60 and a 12-month high of $248.86.
Danaher (NYSE:DHR) last announced its quarterly earnings results on Thursday, January 28th. The conglomerate reported $2.08 EPS for the quarter, topping the Zacks' consensus estimate of $1.84 by $0.24. The business had revenue of $6.76 billion for the quarter, compared to analysts' expectations of $6.62 billion. Danaher had a return on equity of 12.94% and a net margin of 18.05%. The business's quarterly revenue was up 38.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.28 EPS. As a group, research analysts expect that Danaher will post 6.05 earnings per share for the current year.
In other news, SVP Angela S. Lalor sold 6,437 shares of the business's stock in a transaction on Friday, February 12th. The stock was sold at an average price of $244.70, for a total value of $1,575,133.90. Following the completion of the transaction, the senior vice president now owns 25,148 shares in the company, valued at $6,153,715.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.70% of the stock is owned by insiders.
A number of equities research analysts have recently weighed in on DHR shares. Credit Suisse Group lifted their price objective on Danaher from $260.00 to $264.00 and gave the stock an "outperform" rating in a research report on Thursday, January 14th. Needham & Company LLC lifted their price objective on Danaher from $209.00 to $272.00 in a research report on Tuesday, October 27th. Royal Bank of Canada lowered Danaher from an "outperform" rating to a "sector perform" rating and cut their price objective for the stock from $273.00 to $234.00 in a research report on Wednesday, November 25th. KeyCorp began coverage on Danaher in a research report on Monday, November 9th. They set an "overweight" rating and a $280.00 price target on the stock. Finally, The Goldman Sachs Group began coverage on Danaher in a research report on Wednesday, December 2nd. They set a "buy" rating and a $250.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. The stock currently has a consensus rating of "Buy" and a consensus target price of $233.00.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
See Also: Special Purpose Acquisition Company (SPAC)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 REITS Analysts Can't Stop Recommending
There are more than 200 publicly-traded real-estate investment trusts (REITs) that you can buy through your brokerage account. Given the sheer number of REITs, it can be hard to identify which real-estate stocks are going to outperform the market.
Fortunately, Wall Street's brightest minds have already done this for us. Every year, analysts issue approximately 4,000 distinct recommendations for REITs. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firms are giving "strong buy" and "buy" ratings to the same REIT.
This slide show lists the 15 REITs that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "15 REITS Analysts Can't Stop Recommending".